Pneumonia News and Research

Latest Pneumonia News and Research

APUA applauds FDA for acting to limit antibiotics in food-producing animals

The Alliance for the Prudent Use of Antibiotics (APUA) today praised the U.S. Food and Drug Administration (FDA) for acting to limit certain extra label uses of cephalosporins in major animal species – cattle, swine, chickens and turkeys – where misuse and overuse are cause for great concern. Extra label use occurs when use of a drug does not comply with the approved labeling.

6 Jan 2012

Bringing health solutions to women, children

In this Huffington Post "Impact" blog post, Melinda Gates, co-chair of the Bill & Melinda Gates Foundation, writes that she will be visiting Bangladesh to "learn even more about two of the biggest killers of children -- pneumonia and diarrhea," and says "Bangladesh has made incredible progress in recent years, reducing the number of childhood deaths by 65 percent since 1990."

6 Jan 2012

FDA issues order prohibiting certain uses of cephalosporins in food-producing animals

The U.S. Food and Drug Administration today issued an order that prohibits certain uses of the cephalosporin class of antimicrobial drugs in cattle, swine, chickens and turkeys effective April 5, 2012.

5 Jan 2012

Yale study questions accuracy of relying on patient death rates to compare hospital quality

Hospitals, health insurers and patients often rely on patient death rates in hospitals to compare hospital quality. Now a new study by researchers at Yale School of Medicine questions the accuracy of that widely used approach and supports measuring patient deaths over a period of 30 days from admission even after they have left the hospital.

4 Jan 2012

Changes in mouth bacteria precede development of pneumonia in hospital patients

New research from the Yale University School of Medicine discovered changes in mouth bacteria preceded the development of pneumonia in hospital patients. After studying 37 participants over the course of a month, Dr. Samit Joshi, leader of the study, concluded changes in oral bacteria play some role in a person's risk for developing pneumonia.

3 Jan 2012

Pfizer’s Prevenar 13 gets US approval for adults

Health authorities of United States have approved the expansion of Pfizer Inc's Prevnar vaccine for use in adults 50 and older to fight pneumonia, meningitis and other diseases cause by pneumococcus bacteria. The vaccine, which had been approved for children in the United States, is already one of Pfizer's biggest brands and an expanded population of adults could generate more than $1.5 billion in annual sales.

2 Jan 2012

FDA approves Prevnar 13 pneumococcal conjugate vaccine for adults 50 and older

Prevnar 13, a pneumococcal 13-valent conjugate vaccine, was approved today by the U.S. Food and Drug Administration for people ages 50 years and older to prevent pneumonia and invasive disease caused by the bacterium, Streptococcus pneumoniae.

31 Dec 2011

FDA approves Pfizer's Prevnar 13 pneumococcal conjugate vaccine as a single dose for adults

Pfizer Inc. announced today that the U.S. Food and Drug Administration has granted approval of the Company's pneumococcal conjugate vaccine Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) as a single dose for use in adults.

31 Dec 2011

Potential new strategy against bacteria with multi-drug resistant organisms

Vaccines with broader reach might be made by stimulating specialized immune cells to recognize foreign cell membrane proteins that are shared across bacterial species, say researchers from Children's Hospital of Pittsburgh of UPMC and the University of Pittsburgh School of Medicine in a report published online today in Immunity.

23 Dec 2011

Leishmania parasite develops combined resistance against drug, human immune system

Scientists of the Institute of Tropical Medicine (ITG) discovered a parasite that not only had developed resistance against a common medicine, but at the same time had become better in withstanding the human immune system.

22 Dec 2011

Unrestricted family visitation in adult ICU provides wide-reaching benefits

The unrestricted presence and participation of patients' family members and friends provides wide-reaching benefits, both medically and emotionally, according to a new Practice Alert from the American Association of Critical-Care Nurses.

20 Dec 2011

Pfizer, GlaxoSmithKline to increase sales of pneumococcal vaccines through GAVI

Pharmaceutical companies Pfizer and GlaxoSmithKline are increasing their sales of reduced-cost pneumonia vaccines to developing countries through the GAVI Alliance "by more than 50 percent, marking the scale-up of an international program to protect millions of children," Reuters reports.

20 Dec 2011

GSK initiates rhACE2 phase IIa study for Acute Lung Injury

APEIRON Biologics AG announced today that GlaxoSmithKline, exclusive, worldwide licensee for Apeiron's new investigational recombinant human Angiotensin Converting Enzyme 2 (rhACE2, name: GSK2586881, formerly APN01), has initiated a phase IIa study in patients suffering from Acute Lung Injury.

19 Dec 2011

Pfizer enters Prevenar 13 supply agreement to protect children from pneumococcal disease

Pfizer Inc. today announced it has entered into a second supply agreement which will broaden and extend the duration of the Company's commitment to help protect millions of infants and young children in the developing world from pneumococcal disease - the leading cause of vaccine-preventable death in young children.

17 Dec 2011

Research roundup: Insurance coverage in the Great Recession; PCIP vs. CHIP

The researchers how physicians examined claims of lower back back pain and note that part of the "rising economic cost of this epidemic is the burgeoning use of indiscriminate imaging," specifically MRIs. Researchers divided patients into two groups and "the treating physician in group 1 patients was blinded to the MRI results, while the physician for group 2 patients decided on treatment after reviewing the MRI findings."

17 Dec 2011

3-year study identifies key interventions to reduce maternal, newborn, child deaths

A three-year study conducted by the WHO, Aga Khan University, and the Partnership for Maternal, Newborn & Child Health (PMNCH) "has identified key interventions to reduce maternal, newborn and child deaths," PANA/Afrique en Ligne reports.

17 Dec 2011

Study aims to reduce mortality disparities by education

A study in the December issue of the American Sociological Review has brought new understanding as to why death rates for less educated middle aged adults are much higher than for their more educated peers despite increased awareness and treatments aimed at reducing health disparities.

16 Dec 2011

Evidence-based interventions to reduce newborn and maternal mortality

Some 56 evidence-based interventions will sharply reduce the 358,000 women who still die each year during pregnancy and childbirth and the 7.6 million children who die before the age of 5, according to a massive three-year global study.

16 Dec 2011

Statins linked with reduced risk of death among hospitalized flu patients

The two main ways to prevent and control influenza today are annual immunization and antiviral drugs. A team of investigators has found that statins, cholesterol-lowering drugs, may offer an additional treatment to complement these approaches and reduce mortality among patients hospitalized with influenza.

14 Dec 2011

Celgene announces results from azacitidine Phase 1 study on AML

Celgene International Sàrl, a subsidiary of Celgene Corporation, announced results from a multi-center Phase I study that explored multiple dosing schedules of oral azacitidine in 23 patients with acute myeloid leukemia (AML), myelodysplastic syndromes or chronic myelomonocytic leukemia (CMML) who were not candidates for other therapies or who had failed previous regimens.

12 Dec 2011